USA - NASDAQ:PLSE - US74587B1017 - Common Stock
The current stock price of PLSE is 17.7 USD. In the past month the price increased by 17.14%. In the past year, price increased by 10.76%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 27.33 | 233.12B | ||
ISRG | INTUITIVE SURGICAL INC | 55.56 | 160.32B | ||
BSX | BOSTON SCIENTIFIC CORP | 34.5 | 144.66B | ||
SYK | STRYKER CORP | 28.77 | 141.33B | ||
MDT | MEDTRONIC PLC | 17.22 | 122.16B | ||
BDX | BECTON DICKINSON AND CO | 13.12 | 53.65B | ||
IDXX | IDEXX LABORATORIES INC | 53.2 | 51.11B | ||
EW | EDWARDS LIFESCIENCES CORP | 30.26 | 45.66B | ||
RMD | RESMED INC | 28.66 | 40.08B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 16.12 | 34.29B | ||
DXCM | DEXCOM INC | 39.58 | 26.39B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 16.13 | 26.25B |
Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. The company is headquartered in Hayward, California and currently employs 75 full-time employees. The company went IPO on 2016-05-18. The Company’s CellFX Nanosecond Pulsed-Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The company is pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation (AF) and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as surgical soft tissue ablation. Its nsPFA Percutaneous Electrode System consists of a disposable, percutaneous, needle electrode for use with its CellFX Console. Its surgical cardiac ablation clamp is designed for use by cardiac surgeons during the surgical treatment of AF. The CellFX Console is a tunable, software-enabled, console-based platform, designed to accommodate the clinical workflow preferred by physicians. The company is also developing a Nanosecond PFA 360-degree Cardiac Catheter System.
PULSE BIOSCIENCES INC
3957 Point Eden Way
Hayward CALIFORNIA 94545 US
CEO: Darrin R. Uecker
Employees: 75
Phone: 15109064600
The current stock price of PLSE is 17.7 USD. The price decreased by -0.56% in the last trading session.
The exchange symbol of PULSE BIOSCIENCES INC is PLSE and it is listed on the Nasdaq exchange.
PLSE stock is listed on the Nasdaq exchange.
7 analysts have analysed PLSE and the average price target is 22.44 USD. This implies a price increase of 26.78% is expected in the next year compared to the current price of 17.7. Check the PULSE BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
PULSE BIOSCIENCES INC (PLSE) has a market capitalization of 1.19B USD. This makes PLSE a Small Cap stock.
PULSE BIOSCIENCES INC (PLSE) currently has 75 employees.
PULSE BIOSCIENCES INC (PLSE) has a support level at 17.2 and a resistance level at 17.77. Check the full technical report for a detailed analysis of PLSE support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
PLSE does not pay a dividend.
PULSE BIOSCIENCES INC (PLSE) will report earnings on 2025-10-28.
PULSE BIOSCIENCES INC (PLSE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.7).
The outstanding short interest for PULSE BIOSCIENCES INC (PLSE) is 14.47% of its float. Check the ownership tab for more information on the PLSE short interest.
ChartMill assigns a technical rating of 8 / 10 to PLSE. When comparing the yearly performance of all stocks, PLSE is one of the better performing stocks in the market, outperforming 74.82% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to PLSE. PLSE has a great financial health rating, but its profitability evaluates not so good.
Over the last trailing twelve months PLSE reported a non-GAAP Earnings per Share(EPS) of -0.7. The EPS decreased by -33.67% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -56.57% | ||
ROE | -65.11% | ||
Debt/Equity | 0 |
7 analysts have analysed PLSE and the average price target is 22.44 USD. This implies a price increase of 26.78% is expected in the next year compared to the current price of 17.7.